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A new study by Alyamani et al.1 shows that 
the steroidal structure of the CYP17A1 
inhibitor galeterone makes it susceptible 
to conversion into metabolites with differ­
ing activities on the androgen signalling 
pathway. The metabolic pathway of abi­
raterone, another CYP17A1 inhibitor, was 
previously reported by the same group2. 
Although these two agents have a similar 
chemical structure, their activity and that 
of their metabolites differ. The presence of 
active metabolites with possibly un desirable 
effects might be a universal drawback of 
these steroidal drugs.
The androgen receptor (AR) is a sur­
vival factor for normal, as well as malignant, 
prostate cells, and several options to thera­
peutically target the AR signalling pathway 
have been exploited in patients with pros­
tate cancer. As a first option in the hor monal 
treatment of prostate cancer, androgen 
deprivation is obtained by interfering with 
the hypo thalamic– pituitary–gonadal axis. 
Luteinizing­hormone­releasing hormone 
agonists, such as leuprolide or goserelin, are 
used to inhibit the testicular and adrenal pro­
duction of androgens, resulting in slowed or 
halted tumour growth. The cancer eventually 
becomes independent of these extratumoral 
androgens and the prostate cancer cells start 
to grow again, leading to castration­ resistant 
prostate cancer (CRPC). This castration resist­
ance can be caused by AR over expression and 
a concomitant rise in expression of AR splice 
variants (through mutations in AR leading to 
activity of CYP17A1 in  vitro than abira­
terone6. Galeterone also acts as an AR antag­
onist, inducing degradation of wild­type and 
mutant ARs7. Unfortunately, the phase III 
clinical trial in which galeterone was com­
pared with enzalutamide in patients with 
metastatic CRPC positive for expression of 
the AR splice variant AR­V7 (ARMOR3­SV) 
was discontinued last year because of the 
unlikelihood of meeting its trial end point.
This paper by Nima Sharifi’s group1 
gives important new insights into the meta­
bolism of galeterone in preclinical models. 
In human LNCaP prostate cancer cells, 
3β­hydroxysteroid dehydrogenase (3β­HSD) 
converts galeterone to ∆4­galeterone (D4G), 
which is further converted by steroid 
5α­ reductase (SRD5A) to 3­keto­5α­galeterone 
(5αG), which can be further converted to the 
inactive 3α­OH­5α­galeterone by 3α­HSD3. 
In mice, galeterone is also metabolized to 
D4G, as well as to three 5α­reduced and three 
5β­reduced metabolites (FIG. 1). In 2016, the 
same group reported that abiraterone is also 
metabolized into ∆4­abiraterone (D4A), 
5α­abiraterone, and five other steroidal meta­
bolites2. Abiraterone is a specific inhibitor of 
CYP17A1, but the D4A metabolite blocks not 
only CYP17A1 but also 3β­HSD and SRD5A, 
and also acts as a potent AR antagonist. The 
further 5α­reduced or 5β­reduced metabolites 
of D4A have been detected in patient sera and 
3­keto­5α­abiraterone (5αA), which is pres­
ent at high concentrations in patient sera, was 
shown to have AR­agonistic properties.
The first important finding of Alyamani 
et al.1 is that D4A is ~100­fold more potent 
in inhibiting CYP17A1 than galeterone or 
any of its metabolites in a cell culture assay. 
In contrast to abiraterone, galeterone is 
thought to be an AR degrader, and Alyamani 
et al.1 also observed this property for D4G 
and 5αG (the latter only in LNCaP cells); 
however, as this degradation was only seen 
at 10 µM concentrations of both D4G and 
5αG, the clinical relevance of this obser­
vation remains unclear. In addition to its 
functions as a CYP17A1 inhibitor and AR 
degrader, galeterone is also an AR antag­
onist7. Importantly, the 3­keto structure of 
the galeterone metabolites is shared with tes­
tosterone and dihydrotestosterone, whereas 
the 5α­reduced metabolites are planar, sim­
ilar to the more potent dihydrotestosterone. 
mutant or truncated receptor versions), by 
alterations in AR co­regulators or pioneering 
factors that assist in changing the chromatin 
status of androgen target genes, by activa­
tion of alternative signalling pathways that 
affect androgen signalling, or by ectopic, 
intra tumoral synthesis of androgens.
The AR signalling axis is still thera­
peutically targeted in patients with CRPC, 
either with flutamide­like AR antagonists, 
such as enzalutamide or apalutamide, or 
with inhibitors of the androgen biosynthesis. 
Owing to the importance of the remaining 
or intratumoral androgen synthesis in CRPC, 
inhibition of key enzymes in the androgen 
biosynthesis pathway has been developed as 
a therapeutic approach3. As such inhibitors 
mimic natural ligands, steroid scaffolds are 
excellent starting points for their develop­
ment. However, this resemblance can also 
be a major drawback, as it might make them 
susceptible to modifications by the same 
metabolic enzymes that are responsible for 
the synthesis or the clearance of naturally 
occurring steroids4.
Abiraterone is the most commonly used 
inhibitor of steroid 17­α­hydroxylase/17,20 
lyase (CYP17A1), which is the key enzyme 
in androgen biosynthesis, converting preg­
nenolone into the testosterone precursor 
dehydroepiandrosterone. Abiraterone is 
currently in clinical use for the treatment 
of metastatic CRPC5. Galeterone is another 
steroid al CYP17A1 antagonist and is 2.7­fold 
more potent in inhibiting the C17,20­lyase 
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Galeterone is a steroid 17‑α‑hydroxylase/17,20 lyase and androgen receptor 
antagonist intended for patients with prostate cancer. Similar to abiraterone, 
galeterone has a steroid scaffold structure and mimics natural ligands;  
thus, these agents are metabolized by the same enzymes that synthesize or 
degrade naturally occurring steroids, which can result in attenuated efficacy.
Refers to Alyamani, M. et al. Steroidogenic metabolism of galeterone reveals a diversity of biochemical activities.  
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The D4G and 5αG metabolites have an 
apparent affinity for the wild­type AR 
that is similar to that of D4A, whereas 
galeterone itself has a somewhat lower 
affinity. Comparisons of the effects of the 
different metabolites on the expression 
of androgen­ responsive genes in LNCaP 
and VCaP cells showed that the properties 
of galeterone and D4G are very similar to 
those of D4A, whereas 5αG is a less potent 
AR inhibitor than its precursors and even 
showed some partial agonistic activities in 
LNCaP cells (similar to 5αA, as shown in the 
2016 paper)1,2.
Interestingly, combined treatment 
with abiraterone and the SRD5A inhibitor 
dutasteride in patients with prostate can­
cer resulted in an increase in serum D4A 
levels and a decrease in further meta bolites 
with tumour­promoting properties, demon­
strating a way to optimize therapy with 
steroidal CYP17A inhibitors and/or AR 
antagonists2. Whether combining galeterone 
with dutasteride would also prevent galeter­
one conversion into a less active CYP17A1 
inhibitor or AR­agonistic 5αG metabolite in 
patients remains to be investigated.
Patient samples were not available for 
the study by Alyamani et al.1 so metabolism 
of galeterone was studied only in cell lines 
and rodents, possibly limiting the clinical 
relevance of the findings. The enzymes 
involved in steroid metabolism are highly 
conserved across species, but their relative 
activities, expression patterns, and regu­
lation can differ substantially, explaining 
the differences in serum levels of steroids 
between men and rodents8. In addition, 
mice lack the high serum concentrations 
of sex­hormone­binding globulin seen in 
humans, which has an important effect on 
the bioavailability and degradation of bind­
ing steroids9. In conclusion, the metabolic 
pathways described for abiraterone10 and for 
galeterone1 might suggest not only a mech­
anism behind the lower clinical efficacy of 
galeterone compared with abiraterone but 
also a possibly universal problem for the 
clinical use of steroidal drugs with a similar 
∆5,3β­hydroxyl structure.
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Figure 1 | CYP17A1 inhibitor metabolites and their properties. Galeterone 
and abiraterone are metabolized into compounds with differing activities on 
CYP17A1 and the androgen receptor (AR) signalling pathway, owing to their 
steroidal structure. Dutasteride inhibits steroid 5α‑reductase and conversion 
of ∆4‑abiraterone, increasing ∆4‑abiraterone serum levels and decreasing 
levels of metabolites with possible tumour‑promoting properties.
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